Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonesupport Holding AB's revenue for the
three
months ended in Jun. 2026 was kr356 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr1,286 Mil.
Bonesupport Holding AB's Revenue per Share for the
three
months ended in Jun. 2026 was kr5.33.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr19.27.
Warning Sign:
Bonesupport Holding AB revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Bonesupport Holding AB was 21.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 51.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 47.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 25.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Bonesupport Holding AB's highest 3-Year average Revenue per Share Growth Rate was 59.50% per year. The lowest was -1.90% per year. And the median was 20.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BONEXS vs ISRG, BDX, MDLN: Revenue Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's Revenue distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,286 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB (CHIX:BONEXS) has a Revenue of kr1,286 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Bonesupport Holding AB and its competitors.
Is Bonesupport Holding AB's Revenue too high?
Bonesupport Holding AB's current Revenue is kr1,286 Mil. Overall, Bonesupport Holding AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's Revenue compare to ISRG and BDX?
Bonesupport Holding AB's Revenue of kr1,286 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Bonesupport Holding AB and its competitors. Bonesupport Holding AB's current Revenue is kr1,286 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (CHIX:BONEXS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr464.45, compared to a current price of kr219.70 — trading 52.7% below its estimated fair value. The current Revenue is kr1,286 Mil. Bonesupport Holding AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Bonesupport Holding AB (CHIX:BONEXS), the current Revenue is kr1,286 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (CHIX:BONEXS) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of kr219.70 is trading 52.7% below its estimated GF Value™ of kr464.45.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for CHIX:BONEXS:
Revenue: kr1,286 Mil
GF Value™: kr464.45 vs. price of kr219.70 (52.7% below fair value)
No single metric tells the full story. See the CHIX:BONEXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
75GF Score
Get the complete analysis for CHIX:BONEXS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BONEXS has been successfully added to your 
